Hepatocarcinogenesis (Z#2)/mutagenesis during initiation stage

Area of Science:

• Hepatocellular Carcinoma Research
• Transgenic Mouse Models
• Carcinogenesis Studies

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern.
• Developing accurate animal models for HCC is crucial for understanding disease mechanisms.
• Previous work established a Z#2 transgenic mouse model for endogenous HCC development.

Purpose of the Study:

• To evaluate a Z#2 mouse model, also transgenic for the lacI gene, for endogenous carcinogenesis studies.
• To determine the utility of this double transgenic model for in vivo mutagenesis research.
• To assess lacI mutant frequency during the initiation phase of carcinogenesis.

Main Methods:

• Crossing Z#2 mice with Big Blue mice (transgenic for lambda/lacI shuttle vector).
• Utilizing five-month-old double transgenic mice (Z#2+/lacI+).
• Measuring hepatic lacI mutant frequency as a marker for mutagenesis.

Main Results:

• The double transgenic mice exhibited the expected post-inflammatory stage of Z#2 carcinogenesis.
• Hepatic lacI mutant frequencies were measurable (10^-5 to 10^-4), suitable for mutagenesis studies.
• A slight increase (< 2x) in hepatic lacI mutation frequencies was observed in Z#2 transgenic mice compared to controls.

Conclusions:

• The Z#2+/lacI+ mouse model is suitable for studying endogenous carcinogenesis and in vivo mutagenesis.
• Further research is needed to reconcile the observed limited lacI mutagenesis with the high incidence of hepatocarcinogenesis.
• This model provides a valuable tool for investigating the interplay between mutagenesis and cancer initiation.